Dr Reddy’s Laboratories Ltd has launched Hervycta (Trastuzumab), a biosimilar of Roche’s Herceptin in India, indicated for the treatment of HER2-positive cancer (early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Dr. Reddy’s Hervycta is available in strengths of 150 mg and 440 mg multiple dose vials.
Commenting on the launch, MV Ramana, CEO- Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories, said, “ Hervycta is a step forward in our effort to accelerate access to cancer patients in India in the oncology biosimilar space.”
Raymond De Vré, Senior Vice President and Head, Biologics, Dr Reddy’s Laboratories added “The launch of Hervycta will immensely benefit women in India who are suffering from HER2-positive breast cancer and are in need of access to high quality, affordable and innovative medicines.”
Herceptin (marketed as Herclon in India) and its biosimilars had India sales of approximately Rs 290 crore for the most recent 12 months ended December 2017, according to India Tandem Oncology Monitor 2017.
Dr Reddy’s currently has four biosimilar products commercialised in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.